Tracking Extracellular Tumor-Antigen Processing and Presentation in Immune cells for Cancer Cure
MoRE2020 Fellow Ganesh Shelke, outgoing mobility from University of Gothenburg to Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National institute of Health (NIH), Bethesda, MD, USA
Treatment of tumours impacts both economics and quality of life, and this project will enable clinicians to determine if a cancer patient with relapsed tumour will respond to state-of-the-art therapies. This project focus on pancreatic cancer and uveal melanoma as they are aggressive and often detected in their last stages. Despite recent progress in cancer treatment using drug based or immunotherapy regimes, many patients still show tumour relapse. These tumours have acquired resistance and no longer respond to the therapy, but the mechanism behind this transition is unknown. Immunotherapy relies on the ability of immune cells to detect mutated proteins (tumour-associated antigens, TAAs) on the surface of tumour cells and then to kill the tumour cells. However, it is not known how immune cells detect and process these TAAs. We aim to identify the proteins that play a role in processing and presenting the TAAs and to determine if genetic alterations in these proteins can predict cancer occurrence or tumour relapse. Detection of such proteins in antigen-presenting cells (e.g dendritic cells) from cancer patients will help clinicians to predict the effectiveness of immunotherapy. This project will have broad impacts for the development of therapies targeting multiple types of cancer, and thus Sahlgrenska University (SU) Hospital along with the University of Gothenburg (UGOT) are pairing up with the National Institute of Child Health and Human Development (NICHD) at the National Institutes of Health (NIH) in the US to develop a single platform for sharing interdisciplinary expertise to solve a common problem. With this proposal, I believe I can develop new knowledge and technological knowhow that will impact cancer patient’s quality of life and reduce the economic burden of cancer.
Collaborating end-users: Sahlgrenska universitetssjukhus